RNS Number : 7635V
SkinBioTherapeutics PLC
09 March 2026
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or the "Group")
Appointment of the Interim CEO to the SBTX Board of Directors
9 March 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, has confirmed the appointment of Rachel Parsonage, Interim CEO to the Board of Directors. Her appointment was subject to normal regulatory due diligence carried out by the Company's Nominated Adviser, which is now complete.
Martin Hunt, Executive Chairman of SkinBioTherapeutics, said:
"Rachel has been in the post of Interim CEO for just a week so far, and already, she has met the majority of the team and is getting under the skin of the business, including building relationships with our key partners. Her deep experience in leading consumer beauty and wellness companies is evident in her approach, and she has a clear plan of what she wants to achieve in the immediate near term. In the meantime, we are waiting for the outcome of the external investigation as well as preparing for the HY results. We will make further announcements on these events in due course."
-Ends-
The following information is disclosed pursuant to rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:
Directorships or Shadow Directorships held in companies that have entered administration or insolvency:
This Works Limited [Dissolved 20 April 2011] Knowledge and Merchandising Intellectual Property Limited [Voluntarily dissolved 27 December 2011] Enormous Yes Company Limited [Voluntarily dissolved 9 February 2016] ILK Limited [Voluntarily dissolved 2021 and went into administration on 30 June 2023]
Thumbnail image
Interim CEO, Rachel Parsonage
For more information please contact:
Singer Capital Markets(Nominated Adviser & Broker) Philip Davies James Todd Patrick Weaver
+44 (0) 020 7496 3000
Vigo ConsultingMelanie Toyne-Sewell, Rozi Morris
+44 (0) 20 7390 0230SkinBio@vigoconsulting.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.
Background of Rachel Parsonage
Rachel is a seasoned senior executive with over 25 years' experience leading consumer beauty and wellness businesses through growth and change. She has held CEO and transformational level leadership roles across owned and licensed brand portfolios in both domestic and international markets. She has been involved in financial and business model management, operations and inventory management, and the strengthening of corporate governance. Rachel has also worked closely with boards, founders, lenders and partners to navigate periods of transition.
Currently, Rachel runs her own advisory consultancy, Alera Advisory. Before then, she was at KMI Brands for over 16 years, rising from Managing Director to Chief Executive, where she scaled and stabilised a portfolio of owned and licensed beauty brands. Before then, Rachel was Managing Director at This Works, a premium British aromatherapy and skincare brand with UK and US focus, and previously, she was owner of Vita Management, an independent consultancy. Prior to this, she was General Manager at Pacific Direct, a global hotel manufacturing amenity company providing brand development for hotels working with luxury brands, Elemis, Penhaligons and White Company. Rachel is an alumnus of the Business Growth Programme (BGP), part of Cranfield's Executive Development Programme.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAAKFBBBBKDNNK
